SCOTUS setback won’t end FTC’s focus on pharma patent strategies
In AMG Capital Management v FTC, the Supreme Court stripped the Federal Trade Commission of its ability to seek monetary relief for patent-related antitrust infractions.
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.